The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

POSTER
Effects of the Orexin 2 Receptor Agonist ALKS 2680 on qEEG in Patients With Narcolepsy and Idiopathic Hypersomnia
Author(s):

Meera Modi,1 Brendon Yee,2 Julia Chapman,2 Angela D’Rozario,2 Roman Rosipal,3 Leonardo Jose Trejo,3 G.S.F. Ruigt,3 Ron Grunstein,2 Bhaskar Rege,1 Daniel G. Smith1

1Alkermes, Inc., Waltham, MA, USA; 2Woolcock Institute of Medical Research, Sydney, Australia; 3Pacific Development and Technology, Capitola, CA, USA

Content available until 06/07/2028